Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia.

IF 2.3 Q2 ECONOMICS

Journal of Health Economics and Outcomes Research Pub Date : 2025-03-04 eCollection Date: 2025-01-01 DOI:10.36469/001c.129832

Daniel Samacá-Samacá, Antonio Robles, Hugo Ocampo, Francisco J Rodríguez, Carolina Sardi-Correa, Laura Prieto-Pinto, Christian Bührer, Camilo Tamayo, David Rodríguez, Mauricio Hernández-Quintana

{"title":"Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia.","authors":"Daniel Samacá-Samacá, Antonio Robles, Hugo Ocampo, Francisco J Rodríguez, Carolina Sardi-Correa, Laura Prieto-Pinto, Christian Bührer, Camilo Tamayo, David Rodríguez, Mauricio Hernández-Quintana","doi":"10.36469/001c.129832","DOIUrl":null,"url":null,"abstract":"Background: Retinal diseases are major contributors to disability, significantly affecting patients' quality of life. Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic burden in Colombia. Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources. Objective: To estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with DME and nAMD within the Colombian health system. Methods: This study used a 25-year Markov cohort model to estimate the cost-effectiveness of faricimab vs aflibercept, ranibizumab, and brolucizumab. We used the methodological guidelines of the local health technology assessment agency for conducting the cost-effectiveness and budget impact analysis. Transition probabilities and injection frequencies were derived from the literature. Drug prices were retrieved from public local databases. Quality-adjusted life years (QALYs) were assessed. The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations. Results: Faricimab treat-and-extend (T&E) was dominant vs aflibercept T&E (+0.22 QALYs), ranibizumab T&E (+0.55 QALYs), and brolucizumab for 8 to 12 weeks (+0.06 QALYs) in DME, generating cost savings (in US dollars) of <math><mn>3849</mn> <mo>,</mo></math> 1375, and <math><mn>2824</mn> <mo>,</mo> <mi>r</mi> <mi>e</mi> <mi>s</mi> <mi>p</mi> <mi>e</mi> <mi>c</mi> <mi>t</mi> <mi>i</mi> <mi>v</mi> <mi>e</mi> <mi>l</mi> <mi>y</mi> <mo>.</mo> <mi>I</mi> <mi>n</mi> <mi>n</mi> <mi>A</mi> <mi>M</mi> <mi>D</mi> <mo>,</mo> <mi>f</mi> <mi>a</mi> <mi>r</mi> <mi>i</mi> <mi>c</mi> <mi>i</mi> <mi>m</mi> <mi>a</mi> <mi>b</mi> <mi>a</mi> <mi>l</mi> <mi>s</mi> <mi>o</mi> <mi>s</mi> <mi>h</mi> <mi>o</mi> <mi>w</mi> <mi>e</mi> <mi>d</mi> <mi>d</mi> <mi>o</mi> <mi>m</mi> <mi>i</mi> <mi>n</mi> <mi>a</mi> <mi>n</mi> <mi>c</mi> <mi>e</mi> <mi>v</mi> <mi>s</mi> <mi>a</mi> <mi>f</mi> <mi>l</mi> <mi>i</mi> <mi>b</mi> <mi>e</mi> <mi>r</mi> <mi>c</mi> <mi>e</mi> <mi>p</mi> <mi>t</mi> <mi>a</mi> <mi>s</mi> <mi>n</mi> <mi>e</mi> <mi>e</mi> <mi>d</mi> <mi>e</mi> <mi>d</mi> <mo>(</mo> <mo>+</mo> <mn>0.12</mn> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>s</mi> <mo>)</mo> <mo>,</mo> <mi>r</mi> <mi>a</mi> <mi>n</mi> <mi>i</mi> <mi>b</mi> <mi>i</mi> <mi>z</mi> <mi>u</mi> <mi>m</mi> <mi>a</mi> <mi>b</mi> <mi>a</mi> <mi>s</mi> <mi>n</mi> <mi>e</mi> <mi>e</mi> <mi>d</mi> <mi>e</mi> <mi>d</mi> <mo>(</mo> <mo>+</mo> <mn>0.05</mn> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>s</mi> <mo>)</mo> <mo>,</mo> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>b</mi> <mi>r</mi> <mi>o</mi> <mi>l</mi> <mi>u</mi> <mi>c</mi> <mi>i</mi> <mi>z</mi> <mi>u</mi> <mi>m</mi> <mi>a</mi> <mi>b</mi> <mn>8</mn> <mi>t</mi> <mi>o</mi> <mn>12</mn> <mi>w</mi> <mi>e</mi> <mi>e</mi> <mi>k</mi> <mi>s</mi> <mo>(</mo> <mo>+</mo> <mn>0.12</mn> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>s</mi> <mo>)</mo> <mi>w</mi> <mi>i</mi> <mi>t</mi> <mi>h</mi> <mi>s</mi> <mi>a</mi> <mi>v</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>s</mi> <mi>i</mi> <mi>n</mi> <mo>(</mo> <mi>U</mi> <mi>S</mi> <mo>)</mo></math> 7223, <math><mn>5792</mn> <mo>,</mo> <mi>a</mi> <mi>n</mi> <mi>d</mi></math> 6798, respectively. Assuming an annual market share increase for faricimab of 15% for DME and 13% for nAMD, the Colombian Health System could save <math><mn>144</mn> <mi>m</mi> <mi>i</mi> <mi>l</mi> <mi>l</mi> <mi>i</mi> <mi>o</mi> <mi>n</mi> <mi>o</mi> <mi>v</mi> <mi>e</mi> <mi>r</mi> <mn>3</mn> <mi>y</mi> <mi>e</mi> <mi>a</mi> <mi>r</mi> <mi>s</mi> <mo>.</mo> <mi>O</mi> <mi>f</mi> <mi>t</mi> <mi>h</mi> <mi>e</mi> <mi>s</mi> <mi>e</mi> <mi>s</mi> <mi>a</mi> <mi>v</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>s</mi> <mo>,</mo></math> 122.7 million are attributed to drug costs and <math><mn>21.3</mn> <mi>m</mi> <mi>i</mi> <mi>l</mi> <mi>l</mi> <mi>i</mi> <mi>o</mi> <mi>n</mi> <mi>t</mi> <mi>o</mi> <mi>a</mi> <mi>d</mi> <mi>m</mi> <mi>i</mi> <mi>n</mi> <mi>i</mi> <mi>s</mi> <mi>t</mi> <mi>r</mi> <mi>a</mi> <mi>t</mi> <mi>i</mi> <mi>o</mi> <mi>n</mi> <mi>c</mi> <mi>o</mi> <mi>s</mi> <mi>t</mi> <mi>s</mi> <mo>(</mo> <mi>U</mi> <mi>S</mi></math> 1 = Col$4325). Conclusion: Considering a willingness to pay threshold of $5988 per additional QALY, faricimab is a cost-effective alternative for both DME and nAMD for the Colombian healthcare system, showing dominance over other anti-vascular endothelial growth factor agents. Faricimab provides better health outcomes at lower costs vs other treatments.","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"97-105"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884430/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Economics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36469/001c.129832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Retinal diseases are major contributors to disability, significantly affecting patients' quality of life. Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic burden in Colombia. Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources. Objective: To estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with DME and nAMD within the Colombian health system. Methods: This study used a 25-year Markov cohort model to estimate the cost-effectiveness of faricimab vs aflibercept, ranibizumab, and brolucizumab. We used the methodological guidelines of the local health technology assessment agency for conducting the cost-effectiveness and budget impact analysis. Transition probabilities and injection frequencies were derived from the literature. Drug prices were retrieved from public local databases. Quality-adjusted life years (QALYs) were assessed. The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations. Results: Faricimab treat-and-extend (T&E) was dominant vs aflibercept T&E (+0.22 QALYs), ranibizumab T&E (+0.55 QALYs), and brolucizumab for 8 to 12 weeks (+0.06 QALYs) in DME, generating cost savings (in US dollars) of $3849,$ 1375, and $2824, r e s p e c t i v e l y . I n n A M D, f a r i c i m a b a l s o s h o w e d d o m i n a n c e v s a f l i b e r c e p t a s n e e d e d (+ 0.12 Q A L Y s), r a n i b i z u m a b a s n e e d e d (+ 0.05 Q A L Y s), a n d b r o l u c i z u m a b 8 t o 12 w e e k s (+ 0.12 Q A L Y s) w i t h s a v i n g s i n (U S)$ 7223, $5792, a n d$ 6798, respectively. Assuming an annual market share increase for faricimab of 15% for DME and 13% for nAMD, the Colombian Health System could save $144 m i l l i o n o v e r 3 y e a r s . O f t h e s e s a v i n g s,$ 122.7 million are attributed to drug costs and $21.3 m i l l i o n t o a d m i n i s t r a t i o n c o s t s (U S$ 1 = Col$4325). Conclusion: Considering a willingness to pay threshold of $5988 per additional QALY, faricimab is a cost-effective alternative for both DME and nAMD for the Colombian healthcare system, showing dominance over other anti-vascular endothelial growth factor agents. Faricimab provides better health outcomes at lower costs vs other treatments.